Novogen Limited (Novogen) is a drug discovery company. The Company is primarily engaged in pharmaceutical research and development. The Company’s operations include CanTx Inc., its United States-based joint venture company with Yale University. Novogen has two drug technology platforms (the superbenzopyrans (SBPs) and anti-tropomyosins (ATMs)) yielding drug candidates that have application across a range of degenerative diseases. The Company’s product candidates include Cantrixil, Anisina and Trilexium (TRXE-009). The Company’s target indication for Cantrixil is ovarian cancer and Diffuse Intrinsic Pontine Glioma (DIPG) for Trilexium. The initial target pediatric indication for Anisina is neuroblastoma. The Company primarily focuses on four therapeutic areas: oncology, degenerative diseases, regenerative medicine and autoimmune diseases. It is engaged in pre-clinical steps to undergo a Phase I study for Cantrixil, Anisina and Trilexium.
